Historic Shift: Trump Moves Medical Cannabis to Schedule III

Editor's Brief

After decades of advocacy, the moment finally arrived: the Trump administration officially reclassified FDA-approved and state-licensed medical marijuana from Schedule I to Schedule III under federal law. The move, announced Thursday, is the most significant federal cannabis policy shift in U.S. history — but it's not legalization, and the industry knows it.

Alongside rescheduling, federal officials fast-tracked psychedelic research access, the White House weighed in on contested hemp legislation, and advocates are already demanding the next step: clemency for those still imprisoned on cannabis charges. Today's news is dense, consequential, and just the beginning.

Top Story

Medical Marijuana Moves to Schedule III — History Made, Caveats Attached

The Trump administration on Thursday formally moved FDA-approved marijuana products and cannabis sold under qualifying state medical marijuana licenses from Schedule I to Schedule III under the Controlled Substances Act. A new administrative hearing has been set for June 29, 2026 to continue the broader rescheduling review process. This is not a surprise — it was telegraphed for months — but its arrival is still seismic.

What does Schedule III actually mean? It means cannabis is now federally recognized as having accepted medical use and moderate-to-low potential for dependence — the same tier as ketamine and anabolic steroids. Critically, this unlocks relief from IRS Section 280E, the punishing tax code provision that prevented cannabis businesses from deducting normal operating expenses. For dispensaries and multi-state operators, that alone could be transformative.

However, several major caveats deserve attention. Recreational cannabis remains Schedule I. The reclassification applies specifically to medical marijuana sold under state-licensed programs and FDA-approved products — not the entire legal market. Consumers in adult-use states should not expect immediate federal changes to their purchases. Criminal justice reform is also notably absent: advocates from the Last Prisoner Project, NORML, and the Marijuana Policy Project are already calling on Trump to pair rescheduling with clemency for people still incarcerated on cannabis charges.

What to watch next: Will Congress move to codify broader reforms? How will the DEA's June 29 hearing shape the long-term scheduling landscape? And critically — does rescheduling create a regulatory opening for cannabis businesses to access banking, interstate commerce, and research pathways previously blocked? The industry is cautiously enthusiastic, but the hard work is far from over.

Policy & Legalization

280E Tax Relief: The Industry's Biggest Immediate Win

Per analysis from CBIZ, Schedule III status removes cannabis businesses from the grip of IRS Section 280E, which had forced operators to pay taxes on gross revenue rather than net profit. This could dramatically improve cash flow across the industry. Expect restructured balance sheets and new investment activity in the months ahead.

Hemp's Future Hangs in the Balance

While medical cannabis got good news, hemp-derived THC products face a brewing threat: White House officials are actively engaging with pending legislation that could fast-track a ban on hemp-derived THC products. A new GOP amendment seeks to accelerate enforcement of what amounts to a recriminalization of delta-8 and similar compounds. The hemp and CBD sector faces serious uncertainty even as the broader cannabis industry celebrates.

North Carolina Lawmakers Revisit Marijuana Policy

Momentum from the federal rescheduling is already rippling into state capitols. North Carolina lawmakers are revisiting marijuana policy following Trump's announcement, with renewed discussions about a state medical program. It's a reminder that federal signals — even partial ones — can unlock political will at the state level.

Business & Markets

What Comes Next for Cannabis Companies?

MJBizDaily is asking the right question: rescheduling is historic, but the practical path forward for cannabis companies is still being mapped. Banking access, interstate commerce, and research partnerships remain legally complicated. Operators should prepare for a transitional period, not an immediate boom.

Canopy Growth Reacts to the News

Canopy Growth stock moved on Thursday following the rescheduling announcement, per Benzinga. Canadian licensed producers with U.S. exposure are watching closely, as rescheduling could open doors to American market entry or partnerships. Watch this space through Q2 earnings season.

Canadian Cannabis Sales Hold Steady

Statistics Canada reported February retail cannabis sales of C$440.5 million, down 7.9% from January but up 2.0% on a per-day basis due to the shorter month. The Canadian market continues its slow, steady maturation — not explosive growth, but durable demand.

Science & Cultivation

Rescheduling Opens the Research Door

One of the most underreported benefits of Schedule III status is what it does for scientific research. Schedule I restrictions made cannabis studies extraordinarily difficult to conduct legally. With rescheduling, universities, hospitals, and biotech firms face a dramatically lower barrier to study cannabis therapeutics. Expect a surge in clinical trials and peer-reviewed research over the next 2–3 years.

Scientists Engineer Psychedelic-Producing Tobacco Plants

In a genuinely fascinating development from High Times, researchers have successfully rewired tobacco plants to produce psychedelic compounds including psilocybin and DMT. The breakthrough has implications for biotech medicine and, potentially, for how novel compounds are cultivated at scale. It's a glimpse into a future where plant-based medicine is engineered rather than just grown.

Grower Tip: Ditch the Plastic Pots

High Times published a timely reminder for home cultivators: plastic pots may be silently limiting your yields. Root-bound plants in rigid containers suffer restricted oxygen flow and heat stress. Fabric pots promote air pruning, healthier root development, and measurably better harvests — a simple, affordable upgrade with real results.

Culture & Community

Advocates: Rescheduling Without Clemency Is Incomplete

The celebration over Schedule III is tempered by a moral reckoning. Thousands of Americans remain incarcerated for cannabis offenses that are now federally softened or state-legal. Organizations including the Last Prisoner Project and NORML are publicly demanding Trump accompany rescheduling with executive clemency. The movement is far from finished.

When Dispensaries Become the Gatekeepers of Cannabis Culture

High Times explored a fascinating tension this week: Fat Nugs Magazine's "Kids and Cannabis" issue was refused by a partner dispensary, raising questions about who controls acceptable cannabis discourse. As the industry professionalizes, some argue it's sanitizing the culture that built it. Worth reading for anyone who cares about cannabis's roots.

What This Means for Growers

• Research is coming your way: Schedule III will unlock federally funded studies on cannabis cultivation, genetics, and therapeutic compounds. Expect better data on terpene profiles, cannabinoid interactions, and optimal growing conditions within a few years.
• Hemp growers, stay alert: The proposed federal ban on hemp-derived THC products could affect CBD and alternative cannabinoid markets. If you grow hemp for the extract market, monitor the White House hemp legislation closely through summer 2026.
• Fabric pots over plastic — today: High Times' cultivation piece is a direct, actionable tip. If you're still growing in rigid plastic containers, switching to fabric pots is one of the easiest yield improvements available at any scale.
• State medical markets may expand: States like North Carolina reconsidering medical marijuana programs means new legal cultivation opportunities could emerge in previously closed markets over the next 12–18 months.
• Don't confuse rescheduling with federal legalization: Home growers in states where cannabis remains illegal should not interpret Schedule III as a green light. Recreational cannabis is still Schedule I federally. Know your local laws.

Quick Links

Full source links are listed below this article.